Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials - PubMed (original) (raw)
Meta-Analysis
. 2011 Jun;32(12):1493-9.
doi: 10.1093/eurheartj/ehr017. Epub 2011 Mar 18.
Affiliations
- PMID: 21421598
- DOI: 10.1093/eurheartj/ehr017
Meta-Analysis
Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials
Frank A Holtkamp et al. Eur Heart J. 2011 Jun.
Abstract
Aims: The long-term cardioprotective effect of angiotensin receptor blockers (ARBs) is associated with the short-term lowering of its primary target blood pressure, but also with the lowering of albuminuria. Since the individual blood pressure and albuminuria response to an ARB varies between and within an individual, we tested whether the variability and discordance in systolic blood pressure (SBP) and albuminuria response to ARB therapy are associated with its long-term effect on cardiovascular outcomes.
Methods and results: The combined data of the RENAAL and IDNT trials were used. We first investigated the extent of variability and discordance in SBP and albuminuria response (baseline to 6 months). Subsequently, we assessed the combined impact of residual Month 6 SBP and albuminuria level with cardiovascular outcome. In ARB-treated patients, 421 patients (34.5%) either had a reduction in SBP but no reduction in albuminuria, or vice versa, indicating substantial discordance in response in these parameters. The initial reduction in SBP and albuminuria independently correlated with cardiovascular protection: HR per 5 mmHg SBP reduction 0.97 (95% CI 0.94-0.99) and HR per decrement log albuminuria 0.87 (95% CI 0.76-0.99). Across all SBP categories at Month 6, a progressively lower cardiovascular risk was observed with a lower albuminuria level. This was particularly evident in patients who reached the guideline recommended SBP target of ≤130 mmHg.
Conclusion: The SBP and albuminuria response to ARB therapy is variable and discordant. Therapies intervening in the renin-angiotensin-aldosterone system with the aim of improving cardiovascular outcomes may therefore require a dual approach targeting both blood pressure and albuminuria.
Similar articles
- Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial.
Eijkelkamp WB, Zhang Z, Remuzzi G, Parving HH, Cooper ME, Keane WF, Shahinfar S, Gleim GW, Weir MR, Brenner BM, de Zeeuw D. Eijkelkamp WB, et al. J Am Soc Nephrol. 2007 May;18(5):1540-6. doi: 10.1681/ASN.2006050445. Epub 2007 Apr 4. J Am Soc Nephrol. 2007. PMID: 17409317 Clinical Trial. - Visit-to-visit variability in blood pressure and kidney and cardiovascular outcomes in patients with type 2 diabetes and nephropathy: a post hoc analysis from the RENAAL study and the Irbesartan Diabetic Nephropathy Trial.
McMullan CJ, Lambers Heerspink HJ, Parving HH, Dwyer JP, Forman JP, de Zeeuw D. McMullan CJ, et al. Am J Kidney Dis. 2014 Nov;64(5):714-22. doi: 10.1053/j.ajkd.2014.06.008. Epub 2014 Jul 24. Am J Kidney Dis. 2014. PMID: 25064674 Clinical Trial. - The renal protective effect of angiotensin receptor blockers depends on intra-individual response variation in multiple risk markers.
Schievink B, de Zeeuw D, Parving HH, Rossing P, Lambers Heerspink HJ. Schievink B, et al. Br J Clin Pharmacol. 2015 Oct;80(4):678-86. doi: 10.1111/bcp.12655. Epub 2015 May 28. Br J Clin Pharmacol. 2015. PMID: 25872610 Free PMC article. Clinical Trial. - Treatment of diabetic nephropathy with angiotensin II receptor antagonist.
Lewis EJ, Lewis JB. Lewis EJ, et al. Clin Exp Nephrol. 2003 Mar;7(1):1-8. doi: 10.1007/s101570300000. Clin Exp Nephrol. 2003. PMID: 14586737 Review. - The role of angiotensin II antagonism in type 2 diabetes mellitus: a review of renoprotection studies.
Zanella MT, Ribeiro AB. Zanella MT, et al. Clin Ther. 2002 Jul;24(7):1019-34. doi: 10.1016/s0149-2918(02)80016-9. Clin Ther. 2002. PMID: 12182249 Review.
Cited by
- Diabetic Nephropathy: Update on Pillars of Therapy Slowing Progression.
Naaman SC, Bakris GL. Naaman SC, et al. Diabetes Care. 2023 Sep 1;46(9):1574-1586. doi: 10.2337/dci23-0030. Diabetes Care. 2023. PMID: 37625003 Free PMC article. Review. - Optimization of Albuminuria-Lowering Treatment in Diabetes by Crossover Rotation to Four Different Drug Classes: A Randomized Crossover Trial.
Curovic VR, Jongs N, Kroonen MYAM, Zobel EH, Hansen TW, Sen T, Laverman GD, Kooy A, Persson F, Rossing P, Heerspink HJL. Curovic VR, et al. Diabetes Care. 2023 Mar 1;46(3):593-601. doi: 10.2337/dc22-1699. Diabetes Care. 2023. PMID: 36657986 Free PMC article. Clinical Trial. - Studying Telmisartan Plasma Exposure, Kidney Distribution, Receptor Occupancy, and Response in Patients With Type 2 Diabetes Using [11 C]Telmisartan.
van der Hoek S, Mulder DJ, Willemsen ATM, Visser T, Heeres A, Slart RHJA, Elsinga PH, Heerspink HJL, Stevens J. van der Hoek S, et al. Clin Pharmacol Ther. 2022 Dec;112(6):1264-1270. doi: 10.1002/cpt.2744. Epub 2022 Sep 30. Clin Pharmacol Ther. 2022. PMID: 36070078 Free PMC article. - Management of Hypertension in Patients With Diabetic Kidney Disease: Summary of the Joint Association of British Clinical Diabetologists and UK Kidney Association (ABCD-UKKA) Guideline 2021.
Banerjee D, Winocour P, Chowdhury TA, De P, Wahba M, Montero R, Fogarty D, Frankel A, Goldet G, Karalliedde J, Mark PB, Patel D, Pokrajac A, Sharif A, Zac-Varghese S, Bain S, Dasgupta I; Association of British Clinical Diabetologists and The UK Kidney Association. Banerjee D, et al. Kidney Int Rep. 2022 Jan 13;7(4):681-687. doi: 10.1016/j.ekir.2022.01.004. eCollection 2022 Apr. Kidney Int Rep. 2022. PMID: 35497783 Free PMC article. Review. - Management of hypertension and renin-angiotensin-aldosterone system blockade in adults with diabetic kidney disease: Association of British Clinical Diabetologists and the Renal Association UK guideline update 2021.
Banerjee D, Winocour P, Chowdhury TA, De P, Wahba M, Montero R, Fogarty D, Frankel AH, Karalliedde J, Mark PB, Patel DC, Pokrajac A, Sharif A, Zac-Varghese S, Bain S, Dasgupta I; Association of British Clinical Diabetologists and The Renal Association. Banerjee D, et al. BMC Nephrol. 2022 Jan 3;23(1):9. doi: 10.1186/s12882-021-02587-5. BMC Nephrol. 2022. PMID: 34979961 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical